GlobalData on MSN
Acesion begins patient enrolment in AP31969 Phase II AF study
The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results